Gensia Sicor Inc. Changes Its Name to SICOR Inc. To

Gensia Sicor Inc. (Nasdaq: GNSA) today announced that it has officially changed its name to SICOR Inc. following shareholder approval at the Company's Annual Stockholder Meeting, which took place yesterday at the Company headquarters in Irvine, California. In addition to the name change, the Company has also changed its trading ticker symbol to SCRI, under which SICOR will begin trading at the opening of the market on Friday, June 18, 1999. In addition to the name change, SICOR stockholders also approved the re-election of Donald E. Panoz, Michael D. Cannon and Gianpaolo Colla as Class I Directors, the addition of 100,000 share to the SICOR Employee Stock Purchase Plan, the addition of 1.6 million shares to SICOR's Long-term Incentive Plan, and the ratification of Ernst & Young as the Company's independent auditors. SICOR also announced that it has completed its previously announced private placement of approximately $35 million in common stock and warrants with private investors. SICOR intends to use the proceeds to retire short-term and long-term debt and for general corporate purposes. SICOR Inc. is a vertically integrated specialty pharmaceutical company with proven expertise in the development, manufacturing and marketing of multi-source injectable pharmaceuticals. With a strategy of combining both the production of active pharmaceutical ingredients utilizing synthesis or fermentation and state of the art manufacturing facilities, SICOR's primary focus is on the worldwide injectable pharmaceutical market, which currently includes oncology, anesthesiology, cardiology and other therapeutic areas. SICOR operates several manufacturing facilities in Europe, Mexico and the U.S.A., while maintaining the corporate headquarters in Irvine, California. This press release contains forward looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward looking statements, including whether the Company will be successful in expanding its current role in the pharmaceutical industry, whether the Company will be a leading producer of injectable pharmaceuticals and those matters set forth in the risk factors section of SICOR's filings on Forms 10-K and 10-Q with the Securities and Exchange Commission. These forward looking statements represent the Company's judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward looking statements. For more information on the Company, visit SICOR's web site at News releases are also available at no charge through PR Newswire's News On-Call fax service. For a menu of available news releases or to retrieve a specific release made by SICOR, call 800-758-5804, extension 354050. Please retain these numbers for future reference. ots Original Text Service: Gensia Sicor Inc. Internet: Contact: Laurie W. Little of SICOR Inc., 949-455-4879; or Carolyn Bass or Jim Byers, 415-296-7383, or Patricia Walsh or Mark Owen, 212-850- 5600, all of Morgen-Walke Associates, Inc., for SICOR Inc. Company News On-Call: or fax, 800-758-5804, ext. 354050 Web site:

Klíčová slova

Praha, Česká republika (ce)


Přihlásit k odběru

Materiály označené značkou Protext nejsou součástí zpravodajského servisu ČTK a nelze je publikovat pod její značkou. Jde o komerční sdělení zadavatele, který je ve zprávě označen a který za ně nese plnou odpovědnost.